Spotfire

Spotfire, a business unit of TIBCO, specializes in data analytics and visualization software, though recent financial disclosures focus primarily on its role within bioMérieux's in vitro diagnostics portfolio.

Reviewed by 7wData
Share Email

On this page

Profile

Develops diagnostic systems for rapid clinical testing and data analytics software for business intelligence.

Spotfire, a business unit of TIBCO, specializes in data analytics and visualization software, though recent financial disclosures focus primarily on its role within bioMérieux's in vitro diagnostics portfolio. As of 2025, bioMérieux reported €168 million in sales from its SPOTFIRE molecular point-of-care diagnostics system, an 84% annual increase, with an installed base of 6,400 instruments. The system, which delivers rapid test results (15 minutes for respiratory panels), is positioned as a growth driver in bioMérieux's GO•28 strategic plan, targeting a €450 million revenue run rate by 2028.

However, Q1 2026 saw a downward revision in bioMérieux's full-year guidance due to soft respiratory epidemiology, with SPOTFIRE reagents sales growing 31% organically amid broader market headwinds. The product's expansion into vaginitis and meningitis testing reflects its clinical diversification. TIBCO's legacy Spotfire analytics platform, while not detailed in recent filings, historically served enterprises needing interactive data exploration tools.

Track Spotfire and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Hospitals and clinical laboratories
  • Pharmaceutical quality control teams
  • Public health agencies
  • Industrial manufacturers (via TIBCO's legacy analytics tools)

Strengths and what to watch

Strengths

  • SPOTFIRE's 15-minute turnaround time for molecular tests is fastest in the PoC market
  • Installed base grew 110% YoY to 6,400 units in 2025
  • Menu expansion into non-respiratory panels diversifies revenue streams

Watch for

  • Revenue concentration risk: 84% of SPOTFIRE's 2025 growth came from instrument sales
  • BioMérieux cut 2026 revenue guidance to 3-5% organic growth amid soft diagnostics demand
  • Legacy TIBCO analytics face competition from cloud-native BI platforms

Recent moves

Key Information

Founded
1996
Headquarters
Somerville, Mass

Frequently Asked Questions

What is Spotfire used for?

Spotfire develops diagnostic systems for rapid clinical testing and data analytics software for business intelligence. Its SPOTFIRE molecular point-of-care diagnostics system delivers results in 15 minutes, while its legacy analytics platform supports enterprises in interactive data exploration.

How does SPOTFIRE improve clinical diagnostics?

SPOTFIRE offers a 15-minute turnaround time for molecular tests, making it the fastest in the point-of-care market. It supports rapid respiratory panels and has expanded into vaginitis and meningitis testing, enhancing clinical efficiency and diversifying diagnostic applications.

What is bioMérieux's role in Spotfire?

bioMérieux integrates Spotfire into its in vitro diagnostics portfolio, reporting €168 million in SPOTFIRE sales in 2025. The system is a key growth driver in bioMérieux's GO•28 strategic plan, aiming for €450 million in revenue by 2028.

Who uses Spotfire's products?

Spotfire serves hospitals, clinical labs, pharmaceutical quality control teams, and public health agencies with its SPOTFIRE diagnostics. Its legacy TIBCO analytics platform is used by industrial manufacturers for data exploration and business intelligence applications.

What are Spotfire's strengths in diagnostics?

Spotfire's SPOTFIRE system excels with a 15-minute test turnaround, a 110% YoY growth in installed units (6,400 in 2025), and menu expansion into non-respiratory panels. These strengths position it as a leader in rapid molecular diagnostics.

What challenges does Spotfire face?

Spotfire faces revenue concentration risk, with 84% of 2025 growth from instrument sales. bioMérieux revised 2026 guidance to 3-5% organic growth due to soft diagnostics demand. Legacy TIBCO analytics also compete with cloud-native BI platforms.

Sources

  1. www.biomerieux.com — 2025 financial results showing SPOTFIRE sales growth
  2. www.biomerieux.com — Market share and growth targets for SPOTFIRE
  3. www.biomerieux.com — Q1 2026 performance and guidance revision
  4. www.biomerieux.com — H1 2025 SPOTFIRE sales growth of 143%